Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Judy Lane

Englewood, CO Medical Doctor

NPI 1407819584 CMS profile 199153

333 West Hampden Ave,, Suite 310, Englewood, CO 80110

Open in the dashboard

General payments

$343,543

1,252 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Judy Lane of Englewood, CO is reported in the CMS Open Payments database as having received $343,543 across 1,252 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $710 9
2024 General $6,603 20
2023 General $22,100 195
2022 General $66,978 258
2021 General $91,408 231
2020 General $51,755 182
2019 General $103,989 357

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Judy Lane
  • Colorado median
  • Middle half of Colorado
  • National median

In program year 2025, general payments to Judy Lane were reported at $710. Among 17,059 Colorado profiles paid that year, the median was $144 and the middle half received between $41 and $532.

Show as a table
Year Judy Lane Colorado median Middle half National median
2019 $103,989 $137 $40–$561 $163
2020 $51,755 $109 $32–$371 $114
2021 $91,408 $127 $33–$475 $132
2022 $66,978 $136 $40–$504 $149
2023 $22,100 $144 $43–$511 $160
2024 $6,603 $144 $42–$500 $164
2025 $710 $144 $41–$532 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $93,595 191 payments
  2. Amgen Inc. $62,307 139 payments
  3. Biohaven Pharmaceuticals, Inc. $44,256 67 payments
  4. AbbVie, Inc. $35,372 133 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $27,277 67 payments
  6. Teva Pharmaceuticals USA, Inc. $24,997 80 payments
  7. Lundbeck LLC $23,398 69 payments
  8. Allergan Inc. $11,163 65 payments
  9. Impel Pharmaceuticals Inc. $5,846 16 payments
  10. Upsher-Smith Laboratories LLC $2,801 26 payments
  11. Other $12,530 399 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $255,704 150 payments
  2. Consulting Fee $32,877 28 payments
  3. Food and Beverage $28,564 967 payments
  4. Honoraria $16,880 11 payments
  5. Travel and Lodging $9,139 87 payments
  6. Education $294 7 payments
  7. Grant $85 2 payments
Products named General payments · program years 2019–2025
  1. NURTEC ODT $71,533 134 payments
  2. EMGALITY $64,967 132 payments
  3. AIMOVIG $55,500 137 payments
  4. UBRELVY Neuroscience $32,247 76 payments
  5. VYEPTI $21,087 53 payments
  6. QULIPTA $20,402 68 payments
  7. AJOVY Central Nervous System $13,861 40 payments
  8. Ajovy Central Nervous System $10,845 35 payments
  9. UBRELVY Neuroscience $8,629 27 payments
  10. REYVOW $7,981 27 payments
  11. Other $28,549 579 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

71

Median for Specialist: 51

Drug cost

$36,811

Median for Specialist: $1,236

Branded share of claims

42.3%

Median for Specialist: 21.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 11 $16,724
Aimovig Autoinjector Erenumab-Aooe Brand 19 $15,108
Sumatriptan Succinate Generic 28 $4,725
Gabapentin Generic 13 $254

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,049 Part D prescribers listed as Specialist; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
$2,754 — —
UBRELVY
$2,681 11 —
VYEPTI
$237 — —
INGREZZA
$121 — —
KISUNLA
$119 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

1,252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record